Green Thumb Industries Inc. (GTBIF)
(Delayed Data from OTC)
$11.18 USD
+0.15 (1.36%)
Updated Aug 8, 2024 01:34 PM ET
2-Buy of 5 2
A Value A Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GTBIF 11.18 +0.15(1.36%)
Will GTBIF be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GTBIF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GTBIF
Green Thumb Industries Inc. (GTBIF) Upgraded to Buy: Here's What You Should Know
Green Thumb Industries Inc. (GTBIF) Q2 Earnings and Revenues Surpass Estimates
GTBIF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate Verano Holdings Corp. (VRNOF) to Report a Decline in Earnings: What to Look Out for
Green Thumb Industries Inc. (GTBIF) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Agios Pharmaceuticals (AGIO) Surges 6.5%: Is This an Indication of Further Gains?
Other News for GTBIF
Rising High: Exclusive talk with cannabis marketplace Weedmaps
Wall Street Breakfast Podcast: Household Debt Increases In Q2
Green Thumb Cannabis Q2 Financials Reported Increased Adj. EBITDA Results
Cannabis Boom Or Bust: State Trends Marijuana Investors Can't Afford To Ignore In 2Q24
Analysts Offer Insights on Healthcare Companies: Green Thumb Industries (OtherGTBIF) and Annexon Biosciences (ANNX)